From: Use of large scale EHR data to evaluate A1c utilization among sickle cell disease patients
Baseline characteristics | No. of sickle cell disease patients (%)a | |||
---|---|---|---|---|
HF cohort N = 37,151 | Adherent N = 2521 | NA-1 N = 15,470 | NA-4 N = 776 | |
SCD patients with A1c test** | 3927 (11) | 0 | 841 (5) | 446 (57) |
Gender | Â | Â | Â | Â |
 Male | 16,235 (44) | 1119 (44) | 7257 (47) | 332 (43) |
 Female | 20,822 (56) | 1363 (54) | 8193 (53) | 444 (57) |
Age in years: mean (range)* | 30.8 (0–90) | 38.6 (1–86) | 24.5 (6–46) | 51.2 (5–84) |
Race | Â | Â | Â | Â |
 African American** | 23,764 (64) | 2052 (81) | 12,366 (80) | 354 (46) |
 Asian/Pacific Islander* | 401 (1) | 16 (0.6) | 138 (0.9) | 9 (1) |
 Biracial* | 70 (0.2) | 1 (0.04) | 49 (0.3) | 4 (0.5) |
 Caucasian** | 8933 (24) | 290 (12) | 1147 (7) | 301 (39) |
 Hispanic | 169 (0.4) | 5 (0.2) | 62 (0.4) | 6 (0.7) |
 Native American* | 78 (0.2) | 5 (0.2) | 15 (0.1) | 4 (0.5) |
 Other* | 3736 (10) | 152 (6) | 1693 (11) | 98 (13) |
Diagnosis groups | Â | Â | Â | Â |
 SC-Thal (WoC)* | 850 (2) | 59 (2) | 454 (3) | 12 (2) |
 SC-Thal (WC) | 298 (0.1) | 20 (1) | 80 (0.5) | 4 (0.5) |
 HbSS (u)** | 14,712 (40) | 1271 (50) | 5565 (36) | 262 (34) |
 HbSS (WoC)** | 4914 (14) | 414 (16) | 4201 (34) | 218 (28) |
 HbSS (WC)** | 7255 (20) | 524 (21) | 3679 (24) | 224 (29) |
 HbSC (WoC)* | 1194 (3) | 61 (2) | 810 (5) | 7 (1) |
 HbSC (WC)* | 217 (0.6) | 7 (0.3) | 113 (0.7) | 1 (0.1) |
 Other SC (WoC)** | 311 (1) | 67 (3) | 158 (1) | 5 (0.6) |
 Other SC (WC)** | 6874 (19) | 91 (4) | 225 (1) | 15 (2) |